Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPX-COVID-19
- Development stage
- Unknown
- Lead developer
- BioVaxys Technology Corporation
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**DPX-COVID-19** is a peptide-based vaccine candidate developed by IMV Inc. using the proprietary DPX delivery platform, which encapsulates synthetic peptide antigens derived from SARS-CoV-2 spike protein epitopes. It targets four complementary, non-overlapping regions on the spike protein selected for high immunogenicity and potential to block viral infection, attracting antigen-presenting cells to generate robust, durable T-cell and antibody responses without an adjuvant. Intended for COVID-19 prevention, it showed promising preclinical antibody responses after two doses and safety in related DPX programs like DPX-RSV, with plans for Phase 1/2 trials in 2020 involving over 600 volunteers across age groups.[1][2][3]
- Other names
- DPX-COVID-19DPX-COVID19DPX-COVID 19DPX COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on DPX-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPX-COVID-19.